|Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharma company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell’s core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people.
AT A GLANCE | COMPANY NEWS | COMPANY WEBSITE |SEC FILINGS | STOCK QUOTE
Companies To Watch
XXII 0.60 -0.01 ALXA 4.59 +0.08 CGNH 0.37 -0.02 DND.TO 4.20 +0.01 CNDO 9.56 -0.06 DARA 0.7299 -0.0141 DVAX 2.54 +0.01 FCSC 4.80 -0.05 NSPR 2.12 -0.08 KERX 8.03 0.00 LPTN 4.99 +0.05 MNOV 3.14 -0.03 SNWV 0.88 +0.01 SYN 1.4499 +0.0699 TGTX 5.60 +0.08 THLD 5.54 -0.09 TNXP 0.00 N/A VTUS 2.66 -0.10 ZIOP 2.621 +0.601 2013-05-24 15:54